Research Topics
Genomes and Genes
| Nancy E HynesSummaryAffiliation: Friedrich Miescher Institute Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivationThomas Schlange
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
Breast Cancer Res 9:R63. 2007....- Mammary gland growth factors: roles in normal development and in cancerNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Maulbeerestrasse 66, CH 4058 Basel, Switzerland
Cold Spring Harb Perspect Biol 2:a003186. 2010..We will discuss different peptides in the context of normal development and cancer in this review... - Key signalling nodes in mammary gland development and cancer: MycNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
Breast Cancer Res 11:210. 2009..This review will concentrate on Myc as a signaling mediator in the mammary gland, discussing its regulation and function during normal development, as well as its activation and roles in breast cancer... - c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary glandTina Stoelzle
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
BMC Biol 7:63. 2009..Here we investigated functions of c-Myc during mouse mammary gland development using a conditional knockout approach... - PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enoughNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4059 Basel, Switzerland
Cancer Cell 15:353-5. 2009..show that trastuzumab disrupts ligand-independent ErbB2/ErbB3/PI3K complexes and blocks AKT signaling; if PI3K is mutated, complex disruption does not inhibit AKT, which explains why trastuzumab is ineffective in some tumors... - Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasisJulien H Dey
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Cancer Res 70:4151-62. 2010..Of interest are the downregulated matrix metalloproteases (MMP), in particular MMP9, which is essential for metastatic spread of 4T1 tumors... - Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migrationMaria Meira
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
J Cell Sci 122:787-97. 2009..In summary, these data indicate that Memo also regulates actin dynamics by interacting with cofilin and enhancing its function... - WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growthYutaka Matsuda
Friedrich Miescher Institute for Biomedical Research Part of the Novartis Research Foundation, Basel, Switzerland
Breast Cancer Res 11:R32. 2009..Here we examine the role of WNT signaling in breast tumor cell migration and on xenograft outgrowth... - Novel c-MYC target genes mediate differential effects on cell proliferation and migrationDavid Cappellen
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
EMBO Rep 8:70-6. 2007..Our combined genomic and phenotypic analysis indicates that c-MYC functions are cellular-context-dependent and that selectively regulated genes are responsible for its differential properties... - Wnt3a regulates proliferation and migration of HUVEC via canonical and non-canonical Wnt signaling pathwaysIvana Samarzija
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Biochem Biophys Res Commun 386:449-54. 2009..Taken together, our data indicate that Wnt3a induces canonical and non-canonical Wnt signaling in HUVECs, and stimulates their proliferation and migration... - TEL/ETV6 is a signal transducer and activator of transcription 3 (Stat3)-induced repressor of Stat3 activityNicole Schick
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, Basel CH 4058, Switzerland
J Biol Chem 279:38787-96. 2004..Intriguingly, Stat3 repression did not require TEL DNA binding and appeared to proceed via recruitment of TEL to Stat3. Inhibition of Stat3 activity by TEL represents a novel mechanism regulating the Stat3 signaling pathway... - ErbB receptors and signaling pathways in cancerNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Curr Opin Cell Biol 21:177-84. 2009..Finally, mechanisms contributing to resistance to ErbB-targeted therapeutics will also be discussed... - Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclinsMagdalena Koziczak
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
Oncogene 23:3501-8. 2004..In SUM 52 cells, both MAPK and PI3K signaling pathways were suppressed. In conclusion, results shown here describe a mechanism by which FGFR promotes proliferation of breast cancer cells... - The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expressionBérengère Fayard
Friedrich Miescher Institute for Biological Research, Basel, Switzerland
Cancer Res 69:5690-8. 2009..These results suggest that PN-1 might become a prognostic marker in breast cancer... - Memo mediates ErbB2-driven cell motilityRomina Marone
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
Nat Cell Biol 6:515-22. 2004..Our data suggest that Memo controls cell migration by relaying extracellular chemotactic signals to the microtubule cytoskeleton... - Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeuticsPatrizia Sini
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Cancer Res 68:1581-92. 2008.... - Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoliNa Li
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
EMBO J 24:1942-53. 2005..A connection between p21 Cip1 and beta1 integrin as well as FAK was also established in primary mammary cells. These results point to the essential role of beta1 integrin signaling in mammary epithelial cell proliferation... - The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancerAnne Boulay
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Cancer Res 68:3743-51. 2008..In summary, we showed that Ret is a novel proliferative pathway interacting with ER signaling in vitro. Expression of Ret in primary breast tumors suggests that Ret might be a novel therapeutic target in breast cancer... - Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translationMagdalena Koziczak
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland
J Biol Chem 279:50004-11. 2004..Thus, we propose a novel mechanism for controlling cyclin D1 expression downstream of combined activity of ErbB2 and FGFR-4 that involves S6K1-mediated translation... - Targeting ADAMS and ERBBs in lung cancerNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
Cancer Cell 10:7-11. 2006..This minireview will discuss recent findings on possible mechanisms leading to ERBB-targeted therapy resistance and potential means to overcome them... - The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptidesAndrea B Motoyama
Friedrich Miescher Institute, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
Cancer Res 62:3151-8. 2002.... - Targeting ERBB receptors in cancerNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Recent Results Cancer Res 172:45-57. 2007 - BAD: a good therapeutic target?Andrea B Motoyama
Friedrich Miescher Institute, Basel, Switzerland
Breast Cancer Res 5:27-30. 2003..Furthermore, they showed that the major effector of the EGFR-targeted therapy is BAD, a widely expressed BCL-2 family member. These results are promising in light of the role of the EGFR in breast cancer development... - ERBB receptors and cancer: the complexity of targeted inhibitorsNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
Nat Rev Cancer 5:341-54. 2005..We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response... - ErbB receptors: directing key signaling networks throughout lifeThomas Holbro
Friedrich Miescher Institute for Biomedical Research, 4002 Basel, Switzerland
Annu Rev Pharmacol Toxicol 44:195-217. 2004..In this review, we discuss these data in more detail, illustrating the importance of tightly regulated ErbB signaling throughout life... - The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockadePatrizia Sini
Novartis Institute for Biomedical Research, Oncology Research, Basel, Switzerland
Clin Cancer Res 11:4521-32. 2005.... - The ErbB receptors and their role in cancer progressionThomas Holbro
Friedrich Miescher Institute, PO Box 2543, 4002, Basel, Switzerland
Exp Cell Res 284:99-110. 2003..e., ErbB1 cooperates with other classes of receptors, and the ligand-less ErbB2 functions as a heterodimer with other ErbBs... - P-Rex1, a Guanine Exchange Factor that Is Overexpressed in Breast Cancer, Is a Convergence Node for ErbB and CXCR4 SignalingNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
Mol Cell 41:5-7. 2011..2010) show that P-Rex1, a Rac1 GEF, is overexpressed in ER+ and/or ErbB2+ breast cancers, suggesting that P-Rex1 might be a convergence node downstream of these receptors and an attractive therapeutic target... - Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4Gertraud Orend
Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung, PO Box 2543, CH 4002 Basel, Switzerland
Oncogene 22:3917-26. 2003..We therefore propose that syndecan-4 signaling plays a central role in the control of cellular proliferation of anchorage-dependent fibroblasts... - Potential for targeting the fibroblast growth factor receptors in breast cancerNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Cancer Res 70:5199-202. 2010..Finally, to improve the chances for success with FGFR signal transduction inhibitors, strategies to choose appropriate breast cancer patients for treatment will be discussed... - Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cellsGianluca Civenni
Friedrich Miescher Institute, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
EMBO Rep 4:166-71. 2003..Our finding that Wnts transactivate ErbB1 in addition to stimulating the prototypic beta-catenin/TCF pathway may help to explain why wnt1 is a potent oncogene in the mammary gland... - The mTOR pathway in breast cancerNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
J Mammary Gland Biol Neoplasia 11:53-61. 2006.... - MHO1, an evolutionarily conserved gene, is synthetic lethal with PLC1; Mho1p has a role in invasive growthIvan D Schlatter
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
PLoS ONE 7:e32501. 2012..Moreover, a role for Memo in cell motility/invasion appears to be conserved across species... - Therapeutic targeting of signal transduction pathways and proteins in breast cancerNancy E Hynes
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
J Mammary Gland Biol Neoplasia 11:1-2. 2006